What do systematic reviews say?

Low‐level laser therapy vs Placebo (sham) laser therapy

The review found no eligible studies for this question.

• Interventions for iatrogenic inferior alveolar and lingual nerve injury 2014 · Cochrane All outcomes
  SoF row 'Difficulty speaking': This outcome was not reported in the included studies.
  0 studies
  No studies found

Low‐level laser therapy vs Placebo (sham) laser therapy

The review found no eligible studies for this question.

• Interventions for iatrogenic inferior alveolar and lingual nerve injury 2014 · Cochrane All outcomes
  SoF row 'Difficulty eating': This outcome was not reported in the included studies.
  0 studies
  No studies found

Low‐level laser therapy vs Placebo (sham) laser therapy

Low-level laser therapy (photon-plus GaAlAs diode laser; 70 mW… led to higher mechanosensory perception (load in grams to elicit sensation; Semmes… compared with placebo (sham) laser therapy; GRADE not reported.

• Interventions for iatrogenic inferior alveolar and lingual nerve injury 2014 · Cochrane All outcomes
  MD 1.07 [0.17, 1.97]
  2 studies · 26 participants
  GRADE not reported

Low‐level laser therapy vs Placebo (sham) laser therapy

The review found no eligible studies for this question.

• Interventions for iatrogenic inferior alveolar and lingual nerve injury 2014 · Cochrane All outcomes
  Results: 'No studies reported on quality of life ...'. Not reported by the included laser trials.
  0 studies
  No studies found

Low‐level laser therapy vs Placebo (sham) laser therapy

The review found no eligible studies for this question.

• Interventions for iatrogenic inferior alveolar and lingual nerve injury 2014 · Cochrane All outcomes
  SoF row 'Adverse events': This outcome was not reported in the included studies.
  0 studies
  No studies found

Low‐level laser therapy vs Placebo (sham) laser therapy

The review found no eligible studies for this question.

• Interventions for iatrogenic inferior alveolar and lingual nerve injury 2014 · Cochrane All outcomes
  SoF row 'Pain': This outcome was not reported in the included studies.
  0 studies
  No studies found

Low‐level laser therapy vs Placebo (sham) laser therapy

The review found no eligible studies for this question.

• Interventions for iatrogenic inferior alveolar and lingual nerve injury 2014 · Cochrane All outcomes
  SoF row 'Taste': This outcome was not reported in the included studies.
  0 studies
  No studies found

Low‐level laser therapy vs Placebo (sham) laser therapy

Low-level laser therapy (photon-plus GaAlAs diode laser; 70 mW… showed no clear difference in thermosensory (thermal) perception compared with placebo (sham) laser therapy; GRADE not reported.

• Interventions for iatrogenic inferior alveolar and lingual nerve injury 2014 · Cochrane All outcomes
  MD 1.79 [-2.04, 5.62]
  2 studies · 25 participants
  GRADE not reported

Low‐level laser therapy vs Placebo (sham) laser therapy

The review found no eligible studies for this question.

• Interventions for iatrogenic inferior alveolar and lingual nerve injury 2014 · Cochrane All outcomes
  Results: no included study reported quality of life or patient satisfaction. In PUB2 patient satisfaction is merged with quality of life as 'quality of life/patient satisfaction'.
  0 studies
  No studies found

Any intervention for KCOT (e.g. enucleation), alone or combined with an adjunctive therapy (ostectomy, cryotherapy, or Carnoy's solution) vs A different intervention (e.g. enucleation versus marsupialisation), or the same surgical intervention without the adjunctive therapy

The review found no eligible studies for this question.

• Interventions for the treatment of keratocystic odontogenic tumours 2015 · Cochrane All outcomes
  No randomised controlled trials that met the inclusion criteria were identified. In view of the fact that no studies were identified, no data were available for analysis.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  This outcome was not reported in either of the trials.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  No randomised or quasi-randomised controlled trials in people with Von Willebrand disease met the inclusion criteria; no eligible VWD trials were identified.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  Only reported in the Walsh (EACA) trial: in none of the 31 included participants was blood transfusion required.
  1 study · 31 participants
  GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  Mean fall in haemoglobin. Forbes (TXA): 1.4 g/100 mL (placebo) vs 0.3 g/100 mL (TXA). Walsh (EACA): 6.3% (placebo, both centres) vs 3.9% and 3.7% (EACA, centres 1 and 2); differences not significant. Reported in…
  2 studies · 59 participants
  GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  This outcome was not reported in either of the trials.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  Reported in both trials in different ways. Forbes (TXA): mean units of replacement therapy per root extracted 617 IU (range 0 to 15,800) in 11 placebo participants versus 30 IU and 65 IU per root in 2 TXA participants…
  2 studies · 59 participants
  GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  This outcome was not reported in either of the trials.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… probably leads to lower number of postoperative bleeding episodes requiring intervention compared with placebo, no intervention or usual care (with or without placebo) (moderate certainty).

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes

  Up to 10 days postoperative
  RD -0.57 [-0.76, -0.37]
  2 studies · 59 participants
  Moderate

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  Only reported in the Forbes (TXA) trial: over five-day follow-up, mean blood loss per participant 84.1 mL (range 4 to 323) in the placebo group (n=14) versus 61.2 mL (range 1 to 749) in the TXA group (n=14), P = 0.02.
  1 study · 28 participants
  GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes

  Immediate (<24 h) and delayed (24 h to 10 days)
  This outcome was not reported in either of the trials.
  0 studies
  No studies found